Runyu Dong - Concepedia

Author

Runyu Dong

Dana-Farber Cancer Institute ORCID

Also Known As

R P Dong, R. Dong, R.-P. Dong, R.‐P. DONG, Runyu Dong

Publications

581

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Wannan Medical College First Affiliated Hospital of Wannan Medical College

About

Runyu Dong is an author at Dana-Farber Cancer Institute specializing in medicine, autoimmunity, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	67
2	Immunology	2	2	67
3	Autoimmune Disease	2	2	67
4	Cell Biology	1	1	28
5	Pathology	1	1	39

Runyu Dong

Publications

567

Citations

H-Index

Page 1

	Year	Citations
Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response Runyu Dong, Junichi Kameoka, Martin Hegen, The Journal of Immunology	1996	213
Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation Runyu Dong, Kouichi Tachibana, Martin Hegen, The Journal of Immunology	1997	104
Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase Martin Hegen, Junichi Kameoka, Runyu Dong, Immunology	1997	79
Resistance to autoimmune thyroid disease is associated with HLA-DQ. H. Tamai, Akinori Kimura, Runyu Dong, The Journal of Clinical Endocrinology & Metabolism Disease EtiologyImmunologyPathologyImmune-related Gene PolymorphismSequence-specific Oligonucleotide Probes	1994	39
CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer Yanna Li, Zhixiong Wang, Peng Gao, Journal of Translational Medicine	2024	33
Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function Runyu Dong, Kouichi Tachibana, Martin Hegen, Molecular Immunology Cd26 FunctionAnti-cd26 MabsAutoimmune DiseaseImmunologyImmunodominance	1998	28
Circ_0008315 promotes tumorigenesis and cisplatin resistance and acts as a nanotherapeutic target in gastric cancer Fei Yao, Danping Cao, Yanna Li, Journal of Nanobiotechnology	2024	21
ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study John V. Heymach, Runyu Dong, Isaiah W. Dimery, Journal of Clinical Oncology	2004	20
Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA K. Papadopoulos, Wael A. Harb, Ni Lu, Annals of Oncology	2018	15
Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib Runyu Dong, Yao Fei, Yi‐Ren He, Advanced Science	2025	15

Page 1